SEC Form 4 · accession 0001437749-17-020805
Sun BioPharma, Inc. · SNBP
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Ryan Randall Gilbertson
10% Owner
Period of report
Dec 13, 2017
Accepted (ET)
Dec 15, 2017 · 9:49 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001029125
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Dec 13, 2017 | M | 80,000 | $1.875 | A | 567,050 | D | |
| Common StockF1 | Dec 13, 2017 | F | 11,512 | $13.03 | D | 555,538 | D | |
| Common Stock | holding | — | — | — | 28,000 | I | By Total Depth Foundation |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Warrants (right to buy)F2 | $1.875 | Dec 13, 2017 | M | 80,000 | D | Sep 4, 2015 | Jun 4, 2023 | Common Stock | 80,000 | 0 | D |
Explanation of responses
- F1Pursuant to "net issue exercise" feature of underlying warrant, represents average closing bid and ask prices of the Issuer's common stock for the ten trading day period ending five trading days prior to December 13, 2017.
- F2Unless earlier terminated pursuant to its terms, the warrants terminate upon the earliest of June 2023, upon a closing of a change of control of Issuer, or immediately prior to a closing of a firm commitment underwritten initial public offering pursuant to an effective registration statement filed under the Securities Act covering the offering and sale of Issuer common stock.